NCT00019448View on ClinicalTrials.gov

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 1998

Study Completion Date

March 31, 2007

Conditions
Stage IV MelanomaRecurrent Melanoma
Interventions
DRUG

gp100 antigen

DRUG

interleukin-2

Trial Locations (1)

20892

Surgery Branch, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00019448 - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter